ABOUT Recomodulin(ART-123)
  • History of Recomodulin
  • Mechanism of Action
  • The results of the Japanese Phase III clinical study
  • Press release

History of Recomodulin™(ART-123)

Thrombomodulin was discovered in the rabbit lung by Dr. Esmon at the University of Oklahoma (USA) in 1982.1) They demonstrated that thrombomodulin is present on the surface of vascular endothelial cells and serves as an anticlotting factor responsible for blood coagulation regulation in vivo.

Asahi Kasei Pharma began research on thrombomodulin in 1986, and, in cooperation with Dr. Maruyama of Kagoshima University and Dr. Suzuki of Mie University, succeeded in isolating the world's first human thrombomodulin gene in 1987.2)
Subsequently, we identified the active site of thrombomodulin, and successfully produced this extracellular domain in animal cells through genetic engineering.

The resultant soluble human thrombomodulin (thrombomodulin alfa) was tested in the clinic3-5) as therapy for disseminated intravascular coagulation (DIC), and was approved by the Japanese Ministry of Health, Labor and Welfare in January 2008. Given the brand name Recomodulin™(ART-123), it was listed on the National Health Insurance drug price list April 2008 with a commercial launch in May.

History of ART-123 Development

  • 1) Esmon CT, et al. J Biol Chem. 1982;257:7944-7.
  • 2) Suzuki K, et al. EMBO J. 1987;6:1891-7.
  • 3) Nakashima M, et al. J Clin Pharmacol. 1998;38:40-4.
  • 4) Nakashima M, et al. J Clin Pharmacol. 1998;38:540-54.
  • 5) Saito. H. et al. J Thromb Haemost. 2007;5:31-41.